Markets市場LLY

Eli Lilly's $3.8 billion psychedelic deal forces a sector-wide repricing

After years at the speculative edge of drug development, psychedelic medicine has its first large-cap anchor. Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion, a deal that establishes a valuation reference point…

By Adaeze Nwosu·July 17, 2026·二〇二六年七月十七日·2 min read